Cellexus Ltd was formed in 2008 by a group of ten individual shareholders. Up to late 2015, the company developed and validated the CellMaker bioreactor platform for use in the single use bioreactor (SUB) market.
This period saw the company build a number of beta systems, several currently in use in commercial and academic laboratories.
In 2014, Cellexus relocated from Cambridgeshire to Dundee, attracted by the city's reputation as a life sciences hub, its strong links with academia and the NHS, and the support offered by Scottish Enterprise.
Production of the CellMaker was brought in-house in 2014 and following further developments, the system has been proven to be technically superior to all the competition in its class.
The levels of protein production are three times the norm and it has found a niche market in the production of bacteriophage, algae and yeasts.
Following relocation, and in order to drive commercialisation, in 2015 the management team was restructured with the appointment of a full-time Director & General Manager and a commercially focused Chairman. This restructure increased the external focus of the company and has resulted in new distributors and the release of new application notes.